I-SENS, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021
November 12, 2021 at 11:32 am IST
Share
i-SENS, Inc. reported earnings results for the third quarter and nine months ended September 30, 2021. For the third quarter, the company reported sales was KRW 59,009.32 million compared to KRW 50,544.38 million a year ago. Net income was KRW 6,984.09 million compared to KRW 6,082.51 million a year ago. Basic earnings per share from continuing operations was KRW 514 compared to KRW 447 a year ago. Diluted earnings per share from continuing operations was KRW 513 compared to KRW 447 a year ago. Basic earnings per share was KRW 514 compared to KRW 447 a year ago. Diluted earnings per share was KRW 513.
For the nine months, sales was KRW 169,969.34 million compared to KRW 147,918.7 million a year ago. Net income was KRW 22,793.64 million compared to KRW 19,708.74 million a year ago. Basic earnings per share from continuing operations was KRW 1,677 compared to KRW 1,450 a year ago. Diluted earnings per share from continuing operations was KRW 1,673 compared to KRW 1,449 a year ago. Basic earnings per share was KRW 1,677 compared to KRW 1,450 a year ago. Diluted earnings per share was KRW 1,673 compared to KRW 1,449 a year ago.
i-SENS, Inc. is a Korea-based company mainly engaged in the manufacture and sale of biosensors. The Companyâs products consist of blood glucose monitoring systems, including blood glucose monitors, blood glucose meters, glucose monitors, blood glucose meter kits and blood sugar meters under the brand names of CareSens, MedTrust, BGStar, Barozen and others; electrolyte analyzers and cartridges; immunosensors, as well as other related accessories, such as connectors, lancets, blood glucose data management software and lancing devices, among others. The Company distributes its products within domestic market and to overseas markets including Japan, Europe, the United States and others.
I-SENS, INC. 
